Paul Hays joined Vets Plus as CEO in October 2022. He has passionately contributed over 35 years, to the animal health industry; and has earned a reputation or transforming businesses. Paul’s previous roles include: CEO for Virbac North America, where he strengthened the commercial organization and led the successful turnaround of a Warning Letter at their FDA manufacturing site; Vice President of Global Diagnostics for Pfizer Animal Health (now, Zoetis), where he led their entry into diagnostics through the integration of Synbiotics Corporation for which he served as CEO for eight years, where he led a financial turnaround, taking the public company private, planning the exit, and leading the sale to Pfizer; and Chief Commercial Officer for Vets Plus, Inc.
Preceding roles included: progressive senior management roles with Boehringer Ingelheim Vetmedica including Vice President of Sales & Marketing, where he founded both their equine and swine business units. The swine business unit under his leadership was transformative to BI’s business with the launch of the first PRRS and Ileitis vaccines and through the acquisitions of Fermenta and NOBL Laboratories. Subsequently, he served in Germany headquarters as Corporate Vice President of Marketing & Business, then returned to lead the US business as Executive Vice President of U.S. Business Operations. Earlier in his career, he was part of the US start-up team for CIBA Animal Health (later, Novartis) and began his career as sales representative for Coopers Animal Health. He earned a bachelor’s degree in animal science from the University of Missouri.
Outside of work, Paul is a sportsman and enjoys backpacking, boating, and wine. He is married to his college sweetheart, Alberta, and they have two adult children.
